Evommune EVMN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$6.99M-5,414% | $852.32K+407% | $259K+190% | —— | -$126.78K— | ||
| $4.58K-26.4% | $4.71K-39.6% | —— | —— | $6.23K— | ||
| $123.29K-51.3% | —— | —— | —— | $252.91K+144% | ||
| -$424.56K-341% | -$2.75M-4,996% | —— | —— | $175.99K— | ||
| $150.6K-49.6% | $298.86K— | $298.86K— | $298.86K— | $298.86K— | ||
| —— | $24.93K-73.5% | $24.93K— | $24.93K— | $48.95K— | ||
| $897+0.3% | $859+1.9% | —— | —— | $894— | ||
| -$1.22M-604% | $4.47M+4,822% | —— | —— | -$174K— | ||
| -$1.65M-82,992% | $1.72M+4,568% | —— | —— | $1.99K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Evommune generate?
- Evommune (EVMN) generated -$2.9M in operating cash flow over the trailing twelve months.
- Where does Evommune 's cash flow data come from?
- Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
